The meeting was opened by Dr Dorothy Pearson (Christie Hospital, Manchester) who spoke on 'Management of metastatic malignancy -can adult oncology learn from the paediatric field?' She considered several paediatric solid tumours in which the addition of chemotherapy to radiotherapy and surgery had improved relapsefree intervals and survival.
A clear increase in survival could be seen in cases of nephroblastoma treated in Manchester from 1944 to 1974 as actinomycin D (and later vincristine and adriamycin) became available. She stressed that useful single-agent activity in solid tumours, together with optimal dosage and timing, should be established before a particular drug is incorporated in a multi-agent regime. The differences between American and European work in the evaluation of vincristine in nephroblastoma could be explained by variations in scheduling. In the treatment of rhabdomyosarcoma with combination chemotherapy including cyclophosphamide, the single-agent activity of the latter is unproven and it may prejudice the effect of the more active drugs by limiting their dose and by enhancing normal tissue effects.
She then discussed the sequencing of combined modality treatment and indicated that starting chemotherapy before irradiation allowed local disease to regress and distant spread to be treated earlier. In addition, the drug response could be adequately assessed.
She emphasized the need for long-term follow up of patients, especially in conditions such as Ewing's tumour where late recurrences and second malignancies may occur.
The second part of the meeting was introduced by Dr Pearson who illustrated her remarks with survival figures from the Children's Tumour Registry in Manchester. Although combined treatment had provided encouraging results in many tumours, progress in some areasparticularly brain tumourshad been slower.
Dr Ruth Sandland (St Bartholomew's Hospital, London) then talked of 'The advantages of combined radiotherapy and chemotherapy in childhood cancer' and pointed out that, before the days of effective chemotherapy, local control was attempted with surgery with or without radiotherapy. The former was frequently mutilating, whilst kilovoltage irradiation produced poor cosmetic and functional results. Combinations of I Report of meeting of the Section of Radiology held jointly with the Royal College of Radiologists and the British Institute of Radiology, 19 February 1981 0141-0768/81/070551-02/$01.00/0 chemotherapy and megavoltage irradiation have produced good control in such tumours as pelvic rhabdomyosarcoma, reducing the need for pelvic exenteration and urinary diversion. The radiotherapy must be carefully planned and delivered and, in many cases, should be preceded by chemotherapy in order to reduce tumour bulk and to reduce the volume to be irradiated to high dose.
She then discussed Wilms' tumour and how, in the late 1940s, postoperative radiotherapy seemed to improve survival in patients with apparently localized tumours. More recent studies have included chemotherapy, and that conducted by the National Wilms' Tumour Study Group in the United States has shown that radiotherapy is unnecessary in the younger child with early disease and that two-drug chemotherapy is superior to single-agent treatment in the more advanced cases.
The judicious use of combined modality treatment has produced 5-year survival figures such as 90% for retinoblastoma, 85% for nephroblastoma and 70% for Hodgkin's disease, although the results for neuroblastoma (20% fiveyear survival) and non-Hodgkin lymphoma (10%) are less encouraging. Our aim must be to improve the control rate in these tumours and to diminish the morbidity of surgery and radical radiotherapy.
Dr D P Deakin (Christie Hospital, Manchester) then spoke on 'The problems of combined radiotherapy and chemotherapy' and said that, for radiation therapy alone, the normal tissue tolerance dose had been established over many years. However, many drugs produce enhanced radiation effects, and even relatively low radiation doses in conjunction with such drugs as adriamycin and actinomycin D may cause marked reactions within the irradiated area, involving the skin and viscera. Actinomycin D produces 'recall' reactions when given after radiotherapy in the treated area, even after lengthy intervals. Intracranial calcification, apparently due to an angiopathy, has been found in leukaemic children having cranial irradiation and parenteral or intrathecal methotrexate and may result in subtle cognitive defects. A more severe encephalopathy may develop up to a year after treatment and cause dementia and ataxia. The risk seems to be increased by higher radiation doses and more intensive treatment with methotrexate.
Radiation induces new malignancies, but it is not known whether the addition of chemotherapy will increase the rate, although this may be expected from adult data. ([)1981 The Royal Society of Medicine Dr J V Moore (Paterson Laboratories, Manchester), speaking on 'Experimental combinations of cytotoxic drugs and radiation', cited work performed with vincristine which -if given immediately before irradiation of intestinal cells -did not increase cell kill; however, when the cells were exposed to the drug seven hours before irradiation, the cell kill was markedly raised, probably as a result of cells being drawn into cycle. This temporal relationship varies with different drugs and tissues. He indicated that one possible mechanism for the enhanced radiation reaction seen when adriamycin or actinomycin D are added is a reduction in the cell's ability to accumulate sublethal damage. Work at the Royal Marsden Hospital, London, has shown that cyclophosphamide given two to three days before irradiation of normal animal tissues may exert a protective effect. In tumours, the use of chemotherapy prior to irradiation may result in a reduction in the number of hypoxic cells with improved oxygenation. This has been demonstrated in a mouse tumour system where the radiation dose required to produce local control was significantly reduced with prior chemotherapy.
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Secretory IgA and antigen handling in the gut 1 Immunology, like the Impressionist movement in painting, is the art of the unfinished. So with. immunoglobin A (IgA), whose physical properties have been known for many years but whose significance has only just begun to be appreciated. IgA is found in most mucosal secretions, particularly from the gut, as well as in colostrum, milk and saliva; in man this antibody comprises 13% of serum immunoglobulins. IgA is secreted by plasma cells which secrete, at the same time, a divalent junctional or J chain which binds the IgA associated peptide chains into dimers or higher polymers. Those monomers left unbound are not cleared by such organs as the liver and eventually constitute the majority of the IgA present in serum. Almost all dimeric IgA produced by mucosal plasma cells is transported across the mucosa, after binding to epithelial cell surface receptors, the surface secretory component (SC). The SC attaches to the immunoglobulin and gives IgA resistance to proteolytic digestion by gastrointestinal and intracellular enzymes. Some dimeric IgA produced in the gut wall enters the systemic circulation by the thoracic duct to be excreted by the liver. This explains the increase in serum dimeric IgA observed in animals with portacaval shunt (Vaerman et al. 1981 and actively transported from blood to bile by the hepatocytes (Orlans et al. 1978) . Up to half of an intravenously injected dose of 125iodine-Iabelled dimeric IgA is secreted into the bile within five hours. This process only occurs with dimers or higher polymers of IgA, which are able to bind to the secretory component displayed on the sinusoidal surfaces of the hepatocyte membranes (Reynolds et al. 1980) . The SC-IgA complex is then internalized in endocytic vesicles, transported across the hepatocyte cytoplasm and discharged into the biliary canaliculi (Birbeck et al. 1979) .
Direct immunization into Peyer's patches with bacterial antigens produced a high titre of specific IgA antibody in the bile with hardly detectable concentration of this class of antibody in the bloodstream (Hall et al. 1979) . Fewer biliary antibodies are produced after direct splenic or subcutaneous immunization, the serum antibody raised in such circumstances being entirely confined to IgG or IgM class of antibody (Hall et al. 1979 ). These antibodies are not transported to the bile since they are unable to combine with the SC component. Similarly, oral but not systemic immunization with poliovirus in man produces IgA in the gut secretions. This divergence of immune response can be reproduced experimentally with other antigens (Crabbe et al. 1969 , Bazine et at. 1970 . The relationship of IgA 'copro-antibodies' to protection and elimination of pathogens is still undecided. Well documented instances exist of patients who have high titres of antibody to enteric bacteria yet remain colonized 1') 1981 The Royal Society of Medicine
